QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:AGIO

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

$22.25
+0.51 (+2.35%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.89
$22.36
50-Day Range
$21.74
$30.93
52-Week Range
$16.75
$34.76
Volume
445,349 shs
Average Volume
539,830 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.75

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
69.7% Upside
$37.75 Price Target
Short Interest
Bearish
11.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.85mentions of Agios Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.20 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.76) to ($6.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

742nd out of 995 stocks

Pharmaceutical Preparations Industry

361st out of 482 stocks


AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
SVB Securities Keeps Their Buy Rating on Agios Pharma (AGIO)
Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss
Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates
Agios Pharmaceuticals
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings
11/03/2021
Today
3/27/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.75
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+69.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-231,800,000.00
Net Margins
-1,627.82%
Pretax Margin
-1,627.82%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$20.03 per share

Miscellaneous

Free Float
52,808,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
0.96

Key Executives

  • Brian M. Goff
    Chief Executive Officer & Director
  • Cecilia Jones
    Chief Financial Officer
  • Clive Patience
    Chief Technical Operations Officer
  • Sarah Gheuens
    Chief Medical Officer, Head-Research & Development
  • Charlie Newman
    Chief Business Officer













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued 1 year price objectives for Agios Pharmaceuticals' shares. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they predict the company's share price to reach $37.75 in the next twelve months. This suggests a possible upside of 69.7% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of 2023. Since then, AGIO stock has decreased by 20.8% and is now trading at $22.25.
View the best growth stocks for 2023 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($1.48) EPS for the quarter, beating analysts' consensus estimates of ($1.57) by $0.09. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 20.68% and a negative net margin of 1,627.82%. During the same period in the prior year, the business earned ($1.43) earnings per share.

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.01%), Dimensional Fund Advisors LP (3.01%), First Trust Advisors LP (2.97%), Price T Rowe Associates Inc. MD (2.69%), ArrowMark Colorado Holdings LLC (2.62%) and Macquarie Group Ltd. (2.57%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $22.25.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.23 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($4.24) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 390 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 3/27/2023 by MarketBeat.com Staff